Table 2 Changes in laboratory and echocardiographic parameters after treatment with sacubitril/valsartan.

From: Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis

Variables

Very low-dose

Standard dose

p value

(N = 106)

(N = 100)

SBP (mmHg)

Baseline

102.8 ± 12.0

118.7 ± 13.8

 < 0.001

Follow-up

105.2 ± 16.0

115.3 ± 16.2

 < 0.001

∆ Delta

2.4 ± 15.5

− 3.4 ± 17.8

0.014

DBP (mmHg)

Baseline

65.2 ± 10.0

73.6 ± 12.2

 < 0.001

Follow-up

64.9 ± 10.7

70.2 ± 13.1

0.002

∆ Delta

− 0.3 ± 11.1

− 3.4 ± 17.0

0.133

Log NT-proBNP

Baseline

3.1 ± 0.6

3.0 ± 0.6

0.257

Follow-up

2.8 ± 0.7

2.5 ± 0.8

0.030

∆ Delta

− 0.3 ± 0.6

− 0.4 ± 0.6

0.096

LVEDD (mm)

Baseline

65.5 ± 9.4

64.7 ± 7.0

0.447

FOLLOW-up

61.8 ± 9.7

59.8 ± 7.6

0.140

∆ Delta

− 3.8 ± 5.7

− 4.5 ± 6.3

0.420

LVEF (%)

Baseline

25.4 ± 6.1

27.3 ± 5.9

0.026

Follow-up

34.2 ± 12.5

37.3 ± 11.2

0.081

∆ Delta

9.0 ± 12.3

9.9 ± 12

0.610

  1. SBP systolic blood pressure, DBP diastolic blood pressure, NT-proBNP N-terminal prohormone of brain natriuretic peptide, LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction.
Back to article page